Land: Australien
Sprache: Englisch
Quelle: Department of Health (Therapeutic Goods Administration)
methylprednisolone sodium succinate, Quantity: 1.326 g (Equivalent: methylprednisolone, Qty 1 g)
Pfizer Australia Pty Ltd
Injection, powder for
Excipient Ingredients: monobasic sodium phosphate monohydrate; dibasic sodium phosphate; sodium hydroxide
Intravenous, Intramuscular, Rectal
1 vial of diluent - 15.6mL, 1 vial of powder - 1g
Medicine Registered
Not scheduled. Not considered by committee, (S4) Prescription Only Medicine
When oral therapy is not feasible and the strength, dosage form and route of administration of the drug reasonably lend the preparation to the treatment of the condition, SOLU-MEDROL Powder for Injection is indicated only for intravenous or intramuscular use in the following conditions:,Endocrine Disorders,? Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogues may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance).,? Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogues are used).,? Preoperatively and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful.,? Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected.,? C
Visual Identification: White freeze dried cake in vial of powder, colourless diluent in separate vial.;
Registered
1991-08-02
SOLU-MEDROL ® S O L U - M E D R O L ® CONSUMER MEDICINE INFORMATION (CMI) SUMMARY The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. 1. WHY AM I GIVEN SOLU-MEDROL? SOLU-MEDROL contains the active ingredient methylprednisolone sodium succinate. SOLU-MEDROL is used for treatment of various medical conditions including skin diseases, allergic reactions, inflammation of the eyes, respiratory diseases and certain respiratory infections, diseases of the gut, multiple sclerosis, rheumatic disorders, diseases of the blood and treatment of certain glandular conditions. For more information, see Section 1. Why am I given SOLU-MEDROL? in the full CMI. 2. WHAT SHOULD I KNOW BEFORE I RECEIVE SOLU-MEDROL? Do not use if you have ever had an allergic reaction to methylprednisolone sodium succinate or any of the ingredients listed at the end of the CMI. Talk to your doctor if you have any other medical conditions, take any other medicines, or are pregnant or plan to become pregnant or are breastfeeding. For more information, see Section 2. What should I know before I receive SOLU-MEDROL? in the full CMI. 3. WHAT IF I AM TAKING OTHER MEDICINES? Some medicines and food may interfere with SOLU-MEDROL and affect how it works. Tell your doctor if you are taking any other medicines including medicines used to relieve pain or swelling, some antibiotics, oral contraceptives, anticoagulants, anticonvulsants and antidiabetic medicines. A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI. 4. HOW IS SOLU-MEDROL GIVEN? This medicine will be administered under medical supervision. SOLU-MEDROL must be administered by intravenous or intramuscular injection. You must not administer this medicine to yourself. The dose, how often and how long you are treated with SOLU-MEDROL will depend on your medical condition and also on your weight. Your doctor may change the dose and how many times a day you have it, as your condition ch Lesen Sie das vollständige Dokument
Version: pfpsolmv11221 Supersedes: pfpsolmv10321 Page 1 of 30 AUSTRALIAN PRODUCT INFORMATION – SOLU-MEDROL ® AND SOLU-MEDROL ACT-O-VIAL ® (METHYLPREDNISOLONE SODIUM SUCCINATE) 1. NAME OF THE MEDICINE Methylprednisolone sodium succinate 2. QUALITATIVE AND QUANTITATIVE COMPOSITION SOLU-MEDROL is available in several strengths for intravenous (IV) or intramuscular (IM) administration. 40 MG ACT-O-VIAL SYSTEM - Each mL (when mixed) contains methylprednisolone sodium succinate equivalent to 40 mg methylprednisolone; 125 MG ACT-O-VIAL SYSTEM - Each 2 mL (when mixed) contains methylprednisolone sodium succinate equivalent to 125 mg methylprednisolone; 500 MG VIAL WITH DILUENT - Each 8 mL (when mixed as directed) contains methylprednisolone sodium succinate equivalent to 500 mg methylprednisolone; 1 G VIAL WITH DILUENT - Each 15.6 mL (when mixed as directed) contains methylprednisolone sodium succinate equivalent to 1 g methylprednisolone; 2 G VIAL WITH DILUENT - Each 31.2 mL (when mixed as directed) contains methylprednisolone sodium succinate equivalent to 2 g methylprednisolone; 500 MG PLAIN VIAL - Each vial contains methylprednisolone sodium succinate equivalent to 500 mg methylprednisolone; 1 G PLAIN VIAL - Each vial contains methylprednisolone sodium succinate equivalent to 1 g methylprednisolone; For the full list of excipients, see Section 6.1 List of excipients. 3. PHARMACEUTICAL FORM SOLU-MEDROL 40 mg and 125 mg ACT-O-VIAL System - Powder for injection: White freeze dried cake _ _ - Diluent: Clear colourless liquid _ _ SOLU-MEDROL 500 mg, 1 g and 2 g Vials with Diluent - Powder for injection: White freeze dried cake _ _ Version: pfpsolmv11221 Supersedes: pfpsolmv10321 Page 2 of 30 - Diluent: Clear colourless liquid _ _ SOLU-MEDROL 500 mg and 1 g Plain Vials - Powder for injection: White freeze dried cake When necessary, the pH of each formula was adjusted with sodium hydroxide so that the pH of the reconstituted solution is within the USP specified range of 7 to 8 and the tonicities are, for the 40 mg per m Lesen Sie das vollständige Dokument